To investigate how pharmacological inhibition can affect endogenous BACE1 amyloidogenic and amyloidolytic activities in wild-type human neuroblastoma SH-SY5Y cells (Fig. 1), we measured AD-related protein levels in the absence or presence of the BACE1-selective inhibitor VBA2092464 (termed “R3”). This evidence concerns the gene BACE1 and Alzheimer disease.